RAPT Therapeutics (NYSE: RAPT) — Perfil da empresa, notícias e dados financeiros
RAPT Therapeutics is a biopharmaceutical company developing oral therapies for oncology and inflammatory diseases, focusing on precision.
RAPT Therapeutics
RAPT Therapeutics (NASDAQ:RAPT) is a biopharmaceutical company engaged in discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet medical needs in oncology and inflammatory diseases. With a commitment to innovative research, the company is focused on leveraging its proprietary drug discovery platform to advance a pipeline of novel compounds. RAPT Therapeutics aims to create treatments that offer improved outcomes for individuals suffering from cancer and inflammatory diseases. Its projects emphasize targeted therapies designed to selectively modulate the immune system, aiming for precision in treatment with the potential for better safety profiles and efficacy. The key objective for RAPT Therapeutics is to progress its clinical and preclinical programs towards commercialization, ultimately striving to offer new hope and solutions for patients navigating life with challenging conditions.
Resumo
Operações
Produtos e/ou serviços de RAPT Therapeutics
- Flt3 inhibitor program for treating hematologic malignancies, targeting FLT3 mutations in various blood cancers.
- Oral small molecule inhibitors for oncology, focusing on difficult-to-drug targets in solid tumors.
- Cancer immunotherapy research, aiming to improve the efficacy of checkpoint inhibitors.
- Autoimmune disease treatments, utilizing small molecule approaches to address immune dysregulation.
- Inflammatory disease solutions, developing oral medications for chronic inflammations and autoimmune diseases.
- Partnership initiatives for drug discovery and development, collaborating with pharmaceutical companies to expand therapeutic reach.
equipe executiva do RAPT Therapeutics
- Dr. Brian Russell Wong M.D., Ph.D.CEO, President & Director
- Mr. Rodney K. B. YoungCFO, Principal Accounting Officer & Secretary
- Dr. William Ho M.D., Ph.D.Strategic Consultant
- Steve Young Ph.D.Vice President of Technology
- Dr. Dirk G. Brockstedt Ph.D.Chief Scientific Officer
- Mr. Michael ListgartenGeneral Counsel
- Ms. Gwen R. CarscaddenChief Human Resources Officer
- Dr. Paul Kassner Ph.D.Senior Vice President of Biology
- Ms. Jennifer NicholsonSenior Vice President of Regulatory Affairs & Quality Assurance
- Dr. Nipun Davar MBA, Ph.D.Senior Vice President of Technical Operations
Principais indicadores financeiros
Resultados divulgados pela RAPT Therapeutics, em USD.
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -136,1 mi | -129,9 mi | |
| 0 | -127,1 mi | -116,8 mi | |
| 1,5 mi | -85,8 mi | -81,9 mi | |
| 3,8 mi | -69,2 mi | -68,2 mi |